What You Should Know:
- Holy Name Medical
Center based in New Jersey and Israel’s Sheba Medical Center, the largest
medical center in the Middle East announced a strategic partnership to develop
digital health and telehealth solutions, The
Times of Israel reports.
- As part of the partnership, Holy Name’s team will Sheba’s ARC (Accelerate, Redesign, Collaborate) Innovation
Center with the focus of identifying clinical needs and developing
solutions to medical challenges.
- ARC
Read More
Impact of Precision Medicine| News, Policy, Analysis, Insights - HIT Consultant
AWS, PHDA Collaborate to Develop Breast Cancer Screening and Depression Machine Learning Models
What You Should Know:
- Amazon Web Services (AWS) and the Pittsburgh Health Data Alliance (PHDA) announce a collaboration to produce more accurate machine learning models for breast cancer screening and depression.
- In work funded through the PHDA-AWS collaboration, a research team led by Shandong Wu, an associate professor at the University of Pittsburgh Department of Radiology, is using deep-learning systems to analyze mammograms in order to predict the short‐term risk of developing
Read More
Vanderbilt University Medical Center to Create A Precision Medicine Trial Network Focused on Critical Illness
What You Should Know:
- Vanderbilt University Medical Center inks a strategic
partnership with Endpoint Health to create the world’s first precision medicine
trial network focused on critical illness.
- Late-stage interventional trials will evaluate
personalized approaches to existing care and novel targeted therapies.
Vanderbilt University
Medical Center (VUMC) and Endpoint
Health, the first targeted therapeutics company focused on integrated
solutions for critical illnesses, today
Read More
Syapse Appoints David Pomerantz as Chief Commercial Officer
Syapse, a real-world evidence company accelerating the delivery of precision medicine through the Syapse Learning Health Network™, today announced the appointment of David Pomerantz as Chief Commercial Officer. In his new role as Chief Commercial Officer, Pomerantz will lead the future direction of Syapse’s commercial endeavors and expand its life sciences partnerships across the Syapse Learning Network.
Pomerantz Bio/Background
Mr. Pomerantz brings more than 25 years of account
Read More
FDA, Syapse Expand Research to Generate Real-World Data Related to COVID-19 and Cancer
What You Should Know:
The FDA and Syapse announce research collaboration expansion
to address urgent public health challenges including supporting FDA’s goal of
rapid understanding of COVID-19.
As part of the research, Syapse is partnering with FDA’s
Oncology Center of Excellence to investigate methods to derive RWD from
multiple sources including electronic health records, registries and molecular
data
Syapse, a real-world
evidence company accelerating the delivery of precision
Read More
M&A Analysis: 3 Benefits of Siemens Healthineers’ $16.4B Acquisition of Varian Medical
What You Should Know:
- Siemens Healthineers and Varian Medical announce a $16.4B deal in an all-cash transaction on 2nd August 2020.
- Deal expected to close in 1H 2021.
- Varian Medical will maintain its brand name and operate “independently”
- Siemens AG will drop holding in Siemens Healthineers from 85% to 72% as part of the transaction.
News of the deal between Siemens Healthineers and Varian Medical will have caught many industry onlookers off guard on Sunday evening.
Read More
HHS Taps Fenway Health as Pilot Site for Precision Medicine Project
What You Should Know:
- Fenway
Health has been selected as the pilot site to participate in the Advancing
Standards for Precision Medicine (ASPM) project.
- The ASPM project
is focused on how healthcare providers can systematically identify the
socio-economic factors that may impact the health of patients in order to
provide more individualized care that reflects patients’ needs.
Fenway Health, a
Boston, MA-based Federally Qualified Community Health Center (FQCHC)
Read More
Consumer Genetic Tests Accelerate Precision Medicine for Some Providers
Direct-to-consumer (DTC) genetic tests have been on the scene for some time now. The Federal Drug Administration (FDA) approved the first DTC test on three specific BRCA1/BRCA2 breast cancer gene mutations more than two years ago. Six months after that, the agency similarly green-lighted a DTC pharmacogenomic (PGx) test to examine 33 variants for eight different genes that indicate how effectively patients metabolize specific medications.
Like many such advances, availability of DTC tests is
Read More
Syapse Lands $30M to Accelerate Real-World Evidence in Oncology
What You Should Know:
- Syapse raises $30M in new equity funding to enable healthcare providers to deliver the best care to every cancer patient through precision medicine.
- Syapse partners with health systems, life sciences companies, and regulators to deliver clinical, programmatic, and research insights from the world’s largest network of health systems focused on precision medicine.
Syapse, a San
Francisco, CA-based provider of precision oncology
solutions announced $30
Read More
AHA Launches COVID-19 Data Challenge to Address Health Disparities Among African Americans, Hispanics, Native Americans in Rural Areas
What You Need to Know:
- American Heart Association, Hitachi Vantara and BurstIQ launch COVID-19 Data Challenge to bring global COVID-19 datasets to researchers and clinicians to examine the relationship with other health conditions and health disparities.
- Each participant of the challenge will be provided a free, HIPPA compliant and FedRAMP certified, secure Precision Medicine Platform (PMP) workspace to conduct analyses.
The American Heart Association, the
Read More
